Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological disorders, announced that its NGN-401 gene therapy for Rett syndrome has been chosen to participate in the FDA's Support for Clinical Trials

Quince Therapeutics, Inc. has announced today that the U.S. Food and Drug Administration has granted Fast Track designation for its EryDex System for the treatment of Ataxia-Telangiectasia. This system employs a novel drug delivery technology that utilizes the patient's own biology

Keymed Biosciences Inc. presented at the European Academy of Allergy and Clinical Immunology Congress 2024 with data from a Phase III clinical trial of stapokibart injection for moderate-to-severe atopic dermatitis

Catalyst Oncology, a biotech-focused oncology CRO brand under Catalyst Clinical Research, is set to partner with Imerman Angels, a distinguished nonprofit providing personalized one-on-one cancer support free of charge.

Avirmax Biopharma, Inc., a leader in genetic medicine innovation, is pleased to announce that it has obtained Investigational New Drug approval from the U.S. Food and Drug Administration for the initiation of a Phase

Precision for Medicine, a prominent figure in biomarker-driven clinical research and development for life sciences companies, has made an announcement today regarding its acquisition of Algorics, a swiftly growing provider of clinical technologies and biometrics services

Anaveon, a clinical-stage immuno-oncology company, has announced that the FDA has accepted its Investigational New Drug (IND) application. This milestone allows them to move forward with a Phase I/II study to assess the safety and efficacy of ANV600

Eisai Co., Ltd. and Biogen Inc. jointly announced today that the Ministry of Food and Drug Safety in South Korea has given approval for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI"

Be Biopharma, Inc. has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for BE-101, a novel treatment for hemophilia B. This milestone marks a significant step forward in the company's efforts to develop Engineered B Cell Medicines

RevolKa Ltd., a venture-backed biotech company led by Norio Hamamatsu as President and CEO, has forged a significant partnership with Daiichi Sankyo Co., Ltd., under the leadership of President and COO Hiroyuki Okuzawa.